Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Iron May be at Heart of Cancer Drug’s Cardiotoxicity Effect
Disease Discoveries

Iron May be at Heart of Cancer Drug’s Cardiotoxicity Effect

By Roger AndersonJan 17, 2014
Share
Facebook Twitter Email
Cardiac muscle consists of interlacing bundles of cardiomyocytes, the nucleus of which are stained blue. In a recent publication, Hossein Ardehali, MD, PhD, showed that heart damage from the anti-cancer drug doxorubicin is caused because it promotes an accumulation of iron inside mitochondria.

Northwestern Medicine scientists have discovered the role iron plays in weakening a person’s heart following treatment with the common chemotherapy drug doxorubicin (DOX).

Hossein Ardehali, MD, PhD, associate professor in Medicine-Cardiology and Molecular Pharmacology and Biological Chemistry, found that cardiomyopathy, a prevalent side effect of DOX, is dependent on the accumulation of iron inside the mitochondria of cells.

“When we started these experiments we thought the cardiomyopathy-doxorubicin link may have something to do with the mitochondria rather than the notion that the iron buildup was occurring in muscle cells as a whole,” said Dr. Ardehali, a member of the Feinberg Cardiovascular Research Institute and the Robert H. Lurie Comprehensive Cancer Center. “Our investigations showed that to be true.”

The findings were recently published in the Journal of Clinical Investigation.

Used in chemotherapy, doxorubicin is credited as a “wonder drug” for greatly reducing pediatric cancer deaths throughout the 1990s. Although heart damage remains the most serious side effect, DOX is commonly used in the treatment of a wide range of cancers, including those of the breasts, lungs and ovaries.

“It really has revolutionized the field of oncology, but it has this serious drawback,” Dr. Ardehali said. “As an attending I can recall asking why young women treated for breast cancer were developing cardiomyopathy. The response at that time was, ‘We don’t know.’ ”

The Ardehali lab is working to produce a drug to treat doxorubicin-induced cardiomyopathy by reducing iron inside mitochondria. Pictured from left are Arineh Khechaduri; Rosie Wu, MD, PhD; Kannan Mutharasan, MD; Hossein Ardehali, MD, PhD; Marina Bayeva, PhD, Mohsen Ghanefar, MD.

The lab took multiple approaches to finding that answer.

Using an animal model, scientists were able to demonstrate a reversal of doxorubicin-induced cardiomyopathy by removing iron from the mitochondria. The lab also demonstrated that a drug used to treat DOX-induced heart weakness works by reducing mitochondrial iron, something that hadn’t previously been shown.

“In this publication, we were able to produce several different lines of evidence: genetic, pharmacological and patient samples to prove this uptick in mitochondrial iron was one of the culprits,” Dr. Ardehali said. “Doxorubicin has been around for several decades, but no one had been able to determine why it caused cardiomyopathy.”

Combined with a recent paper suggesting a specific protein also plays a role in heart damage, Dr. Ardehali believes scientists have now identified two independent pathways involved.

Moving forward, the lab will work to produce a drug that would specifically reduce mitochondrial iron to treat doxorubicin-induced cardiomyopathy. Dr. Ardehali’s group has already identified a number of potential compounds and is working in collaboration with the Center for Molecular Innovation and Drug Discovery (CMIDD) to begin preclinical trials.

“One of the advantages of being a physician-scientist is that I see the clinical aspects of medicine and also have the ability to look at the molecular mechanisms causing disease,” Dr. Ardehali said. “Scientists have made great advancements but there remain many diseases where we still can’t explain what is happening. This is no longer one of them.”

The project was funded by National Institutes of Health grants HL107448, HL087149, HL104181, and HL108795.

Cardiology Patient Care Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

Comments are closed.

Latest News

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.